Mayne enters US women’s health market with NASDAQ-listed partner for $205m; shareholders spookedIn a deal the company expects to be immediately material to its own revenues and profits, Australia’s Mayne Pharma (ASX:MYX) is entering the US women’s healthcare product market with NASDAQ-listed partner TherapeuticsMD. Executing a licencing agreement with Therapeutics, Mayne will hand the former $205.5m to fund the product-line acquisition.Payments to Therapeutics MD by Mayne will be made on sales-based milestones; for every US$100m in revenue made each year, Mayne will need to hand TherapeuticsMD $5m. Mayne will also pay royalties of US$3m a year for 12 years.
- Forums
- ASX - By Stock
- MYX
- Mayne Pharma has an extensive women’s health portfolio focused on contraceptives.
Mayne Pharma has an extensive women’s health portfolio focused on contraceptives.
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$4.65 |
Change
0.170(3.79%) |
Mkt cap ! $395.5M |
Open | High | Low | Value | Volume |
$4.50 | $4.68 | $4.47 | $1.532M | 331.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 206 | $4.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.65 | 262 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 206 | 4.630 |
1 | 206 | 4.620 |
1 | 206 | 4.610 |
2 | 10206 | 4.600 |
4 | 2279 | 4.590 |
Price($) | Vol. | No. |
---|---|---|
4.650 | 262 | 1 |
4.660 | 873 | 1 |
4.670 | 1079 | 2 |
4.680 | 1416 | 2 |
4.690 | 206 | 1 |
Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
Last
$4.61 |
  |
Change
0.170 ( 2.41 %) |
|||
Open | High | Low | Volume | ||
$4.47 | $4.68 | $4.47 | 64875 | ||
Last updated 15.59pm 14/06/2024 ? |
Featured News
MYX (ASX) Chart |